{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:19:40Z","timestamp":1784546380301,"version":"3.55.0"},"reference-count":21,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Waikato District Health Board"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>M\u0101ori, the indigenous people of Aotearoa\/New Zealand, have an increased incidence of Graves disease and often require more than one radioiodine (RAI) dose, raising the question as to whether surgery may be preferable in this population. However, there is a lack of outcome data after definitive therapy in an indigenous population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To assess ethnic differences in thyroid status after definitive therapy for Graves disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Single-center retrospective review of patients treated by RAI or thyroidectomy from 1 December 2001 to 31 March 2013. TSH levels at 1, 2, 5, and 10 years after treatment were recorded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 798 patients were included: 589 received RAI, and 209 underwent surgery. Overall, 48% of patients were euthyroid at 1 year after definitive treatment, and 63.5% were euthyroid by 10 years. M\u0101ori were less likely to be euthyroid when compared with Europeans at all time points (e.g., 29.7% vs 57.3% at 1 year and 52.2% vs 70.9% at 10 years, P &lt; 0.0005). M\u0101ori were more likely to receive more than one dose of RAI compared with Europeans (30.2% vs 14.2%, P &lt; 0.0005). Persistent thyrotoxicosis at 1 year after RAI was seen in 25.8% of M\u0101ori compared with 8.3% of Europeans (P &lt; 0.0005).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>M\u0101ori have lower rates of optimal thyroid levels than their European counterparts at all time points studied. Early disparity was associated with a higher RAI failure rate. Late differences were due to higher rates of untreated hypothyroidism. Overall, euthyroid rates were low, indicating the need for improvement in care, particularly for indigenous peoples.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/js.2019-00111","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T09:12:47Z","timestamp":1557997967000},"page":"1335-1344","source":"Crossref","is-referenced-by-count":5,"title":["Inequitable Long-Term Outcomes for an Indigenous Population After Definitive Treatment of Patients With Graves Disease"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4144-4316","authenticated-orcid":false,"given":"Jade A U","family":"Tamatea","sequence":"first","affiliation":[{"name":"Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelson","family":"Tu'akoi","sequence":"additional","affiliation":[{"name":"Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goswin Y","family":"Meyer-Rochow","sequence":"additional","affiliation":[{"name":"Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand"},{"name":"Department of Surgery, Waikato Hospital, Hamilton, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0707-4988","authenticated-orcid":false,"given":"John V","family":"Conaglen","sequence":"additional","affiliation":[{"name":"Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-2300","authenticated-orcid":false,"given":"Marianne S","family":"Elston","sequence":"additional","affiliation":[{"name":"Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand"},{"name":"Department of Endocrinology, Waikato Hospital, Hamilton, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,5,16]]},"reference":[{"issue":"2","key":"2019070309425195300_bib1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2265.1990.tb00489.x","article-title":"The epidemiology of thyrotoxicosis in New Zealand: incidence and geographical distribution in north Canterbury, 1983-1985","volume":"33","author":"Brownlie","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019070309425195300_bib2","author":"Tamatea"},{"key":"2019070309425195300_bib3","doi-asserted-by":"crossref","first-page":"7863867","DOI":"10.1155\/2016\/7863867","article-title":"Response to radioiodine therapy for thyrotoxicosis: disparate outcomes for an indigenous population","volume":"2016","author":"Tamatea","year":"2016","journal-title":"Int J Endocrinol"},{"issue":"2","key":"2019070309425195300_bib4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1245\/s10434-012-2606-x","article-title":"What is the best definitive treatment for Graves\u2019 disease? A systematic review of the existing literature","volume":"20","author":"Genovese","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2019070309425195300_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4158\/EP09257.OR","article-title":"Sex and age differences in levothyroxine dosage requirement","volume":"16","author":"Jonklaas","year":"2010","journal-title":"Endocr Pract"},{"issue":"368","key":"2019070309425195300_bib6","first-page":"107","article-title":"Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment","volume":"43","author":"Parle","year":"1993","journal-title":"Br J Gen Pract"},{"issue":"4","key":"2019070309425195300_bib7","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1210\/jc.2008-1696","article-title":"High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over","volume":"94","author":"Somwaru","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019070309425195300_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/2230-8210.126582","article-title":"Are patients with primary hypothyroidism in India receiving appropriate thyroxine replacement? An observational study","volume":"18","author":"Mithal","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"issue":"5","key":"2019070309425195300_bib9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/qjmed\/hcq222","article-title":"Adequacy of thyroid hormone replacement in a general population","volume":"104","author":"Okosieme","year":"2011","journal-title":"QJM"},{"issue":"1","key":"2019070309425195300_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ando.2012.11.001","article-title":"Do we treat hypothyroidism properly? A survey of 2488 patients from University Hospital Center, Zagreb, Croatia","volume":"74","author":"Solter","year":"2013","journal-title":"Ann Endocrinol (Paris)"},{"issue":"10040","key":"2019070309425195300_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(16)00345-7","article-title":"Indigenous and tribal peoples\u2019 health (The Lancet-Lowitja Institute Global Collaboration): a population study","volume":"388","author":"Anderson","year":"2016","journal-title":"Lancet"},{"key":"2019070309425195300_bib12","article-title":"The United Nations declaration on the rights of indigenous peoples","author":"United Nations","year":"2013"},{"issue":"4","key":"2019070309425195300_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1445-2197.2012.06233.x","article-title":"Thyroid cancer in Graves\u2019 disease: is surgery the best treatment for Graves\u2019 disease","volume":"84","author":"Tamatea","year":"2014","journal-title":"ANZ J Surg"},{"key":"2019070309425195300_bib14","article-title":"Ethnicity data protocols for the health and disability sector","author":"Ministry of Health","year":"2004"},{"key":"2019070309425195300_bib15","unstructured":"Statistics New Zealand. Census quickstats about Maori. 2013; www.stats.govt.nz. Accessed 8 September 2015."},{"key":"2019070309425195300_bib16","author":"Robson"},{"issue":"391","key":"2019070309425195300_bib17","first-page":"93","article-title":"Do abnormal thyroid stimulating hormone level values result in treatment changes? A study of patients on thyroxine in one general practice","volume":"45","author":"De Whalley","year":"1995","journal-title":"Br J Gen Pract"},{"issue":"2","key":"2019070309425195300_bib18","doi-asserted-by":"crossref","first-page":"e019970","DOI":"10.1136\/bmjopen-2017-019970","article-title":"Attitudes and perceptions of health professionals towards management of hypothyroidism in general practice: a qualitative interview study","volume":"8","author":"Dew","year":"2018","journal-title":"BMJ Open"},{"issue":"7","key":"2019070309425195300_bib19","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1210\/jc.2017-00166","article-title":"Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH","volume":"102","author":"Lillevang-Johansen","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019070309425195300_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000438750","article-title":"The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism","volume":"4","author":"Biondi","year":"2015","journal-title":"Eur Thyroid J"},{"issue":"10","key":"2019070309425195300_bib21","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/js.2019-00111\/28648268\/js.2019-00111.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/3\/7\/1335\/28900661\/js.2019-00111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T09:43:28Z","timestamp":1562147008000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/3\/7\/1335\/5489461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,16]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,5,16]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/js.2019-00111","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,5,16]]}}}